4,12-SECO-4,12-DIHYDRORYANODIN


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	GNYCXTYUXOEDDT-OTINFUGDSA-N
Smiles	CC(C)[C@@]1(O)[C@@H](OC(=O)c2ccc[nH]2)[C@@H](O)[C@@]3(C)C[C@]4(O)O[C@@]5([C@H](O)[C@@H](C)CC[C@]35O)[C@@H](O)[C@]14C
InChI	InChI=1S/C25H37NO9/c1-12(2)24(33)17(34-18(29)14-7-6-10-26-14)16(28)20(4)11-23(32)21(24,5)19(30)25(35-23)15(27)13(3)8-9-22(20,25)31/h6-7,10,12-13,15-17,19,26-28,30-33H,8-9,11H2,1-5H3/t13-,15+,16+,17-,19-,20+,21-,22-,23-,24+,25-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C25H37NO9
Molecular Weight	495.56
AlogP	0.32
Hydrogen Bond Acceptor	9.0
Hydrogen Bond Donor	7.0
Number of Rotational Bond	4.0
Polar Surface Area	172.7
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	35.0

Assay Description	Organism	Bioactivity
Binding affinity to ryanodine receptor in Mus musculus albino Swiss-Webster (mouse) brain relative to ryanodine	Mus musculus	5.4
Displacement of [3H]ryanodine from Ca2+-ryanodine receptor in Oryctolagus cuniculus (rabbit) skeletal muscle sarcoplasmic reticulum after 1 hr by competitive inhibition assay in presence of ATP relative to ryanodine	Oryctolagus cuniculus	5.3
Displacement of [3H]ryanodine from Ca2+-ryanodine receptor in Oryctolagus cuniculus (rabbit) skeletal muscle sarcoplasmic reticulum after 2 hr by competitive inhibition assay relative to ryanodine	Oryctolagus cuniculus	4.7

Cross References

Resources	Reference
ChEMBL	CHEMBL2273074
PubChem	76334323

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).